



celsis®

RAPID MICROBIAL DETECTION

Presented By:

# PRESERVATIVE REDUCTION

With Increasing Regulatory Framework

- The main regulatory framework for finished cosmetic products placed on the EU market is Regulation (EC) 1223/2009 on cosmetic products (EU Cosmetics Regulation)
- Governance on substances that may, or may not, be included in cosmetic products.
  - Annex II – Prohibited substances
  - Annex III – Restricted Substances
  - Annex IV – Colorants
  - **Annex V – Preservatives**
  - Annex VI – UV-Filters



# ANNEX V - PRESERVATIVES

## Allowable & Unallowable

- Governs the use of list of allowable preservatives in 28 countries.
- By default, this list also indicates which preservatives are not allowed by exclusion
  - Ex: Methylisothiazolinone, commonly used but no longer allowed.
- Governs acceptable use under certain concentrations.
  - Ex: Poly hexamethylene biguinide hydrochloride (PHMB) must now be used at  $< 0.1\%$
- While list contains 50+ approved preservatives, few options exist.
  - Preservatives must be compatible with formulation

# THE PROBLEM WITH PRESERVATIVES...

## Dwindling options

- Preservatives that are not aligned with Annex V must be discontinued or used in reduced concentrations.
- Allowed preservatives are often pH-dependent, temperature sensitive or specific to formula.
  - Sometimes requires re-formulation around the preservative alone.
  - Introduces risk of failure if not properly evaluated for antimicrobial activity, sensitivity, and long-term stability.
- Alternative preservatives do not have the long term data that the old, standby preservatives have.
  - Additional requirements and longer time-to-market to allow for proper risk assessment.





the old methods of dirty manufacturing are  
**no longer acceptable**



**Cosmetic manufacturers must be concerned about the safety of their ingredients while ensuring their product is free of contamination.**

# KEEPING PACE WITH REGULATORY EXPECTATIONS

...and responding to the pressures of business

- Pressure to release product to market as fast as possible, while ensuring the safety of its ingredients and from adulteration.
- Consumer demands are trending toward preservative-free, all natural formulation claims, while they still expect a clean product.
- Regulatory requirements continue to increase, while the amount of allowable preservatives in your product continues to **decrease**, with few new options coming to market.



Production can **no longer** rely on their preservatives to keep their product clean and free of microbial contamination and must adapt or fail in the eyes of regulators and the consumer.

# ANTIMICROBIAL ACTIVITY BEGINS IN PRODUCTION

Not with Formulation

- Antimicrobial activity is a primary criteria in selection of a preservative system.
- Microbial contamination is primarily introduced through three main points, both of which are in your manufacturing process:
  - Water used in production.
  - The raw materials and ingredients of your product.
  - Your environment and your personnel.
- These initial sources of contamination, lead to continual sources of contamination in your equipment.





Is unknown or uncontrolled microbial contamination during production making you

**preservative-dependent?**

Why not **control your process** instead?

# ACHIEVING A STATE OF CLEAN-BY-DESIGN

## Reducing Risk by Proactive Quality

- Manufacturers need to adapt to increased regulatory demand and consumer expectations by adopting cGMP (current Good Manufacturing Practices) standards for their production process.
- cGMP's involve consistent, well-documented, and proven practices for inspection of:
  - Environmental sampling of equipment, personnel, and manufacturing areas.
  - Microbial testing of water, raw materials, and finished products.
  - Secure, complete, and appropriate documentation of results and records.

# ADDITIONAL GUIDANCE

---

- Guidance can be found in:
  - ISO 22716:2007 - Cosmetics - Guidelines on Good Manufacturing Practices
  - FDA Guidance For Industry - Cosmetic Good Manufacturing Practices



Raw materials, in-process samples, and final product testing should be implemented as part of a **good manufacturing process** addressing contamination earlier and faster.



# ALTERNATIVE MICROBIAL DETECTION METHODS

- Rapid microbial detection technology allows companies to quickly and accurately determine whether a product is contaminated, identify the exact organism, and confirm the quality of the product.


Just being rapid isn't enough.  
Your RMM needs to be the

# Right Microbial Method

Choosing a rapid method takes more time, energy, and money than ever before. And that's even before you consider what you'll need to implement it and ensure it works with your products and methods.



# IMPACT OF CELSIS<sup>®</sup> RAPID MICROBIAL METHODS





celsis®

Rapid Microbial Detection Instruments



# BUILT FOR SIMPLICITY

Celsis<sup>®</sup> Rapid Microbial Detection Instruments

**Easy** integration

Into your current test protocols.  
Use your validated method.  
Eliminate days of incubation.

**Objective** results

replace manual eye counts  
or visual turbidity checks with  
automated, instrument based  
analysis.

**Secure** data integrity

and control through on-board,  
regulatory compliant software.  
Automated reporting. Multiuser  
management.

**Microbial Limits  
results in 24 hours.**

**Because finding  
nothing ultimately  
means everything.**

**Let your data work  
for you, instead of  
against you.**

# SAME FEATURES. DIFFERENT SIZES.

Celsis® Rapid Microbial Detection Instruments

## the Celsis Advance II™

**High capacity. High efficiency.**

Up to 120 Assays per Hour



Provides the critical results necessary for critical decisions. Shorten production cycles. Detect contamination events sooner and respond even faster.


## the Celsis Accel®

**Everything you need. Nothing you don't.**

Up to 30 Assays per Hour



Provides the same high-performance detection and reagent compatibility as the Advance II for labs with workloads that are smaller, but no less important.





celsis®

ATP-Bioluminescence Reagents

# CELSIS LUMISCREEN™ STANDARD ATP BIOLUMINESCENCE

Celsis® ATP-Bioluminescence Reagents


- Adenosine triphosphate (ATP) is present in all living cells, including bacteria, yeasts, and fungi.
- Standard ATP assays use enzyme luciferase to catalyse microbial ATP and produce light
- Light generated is measured using a luminometer.



# CELSIS AMPISCREEN® AMPLIFIED ATP BIOLUMINESCENCE

## Celsis® ATP-Bioluminescence Reagents

- Two-phase, proprietary enzyme reaction
- All living organisms also contain the enzyme adenylate kinase (AK) as part of their biochemical processes
- Microbial enzymes convert ADP into ATP
- Amplification of ATP levels beyond naturally occurring level.
- Enzymes are not depleted by reaction
- Ability to generate almost unlimited amounts of ATP





## ROBUST REAGENTS. RAPID RESULTS.

Celsis<sup>®</sup> ATP-Bioluminescence Reagents

A rapid microbial detection instrument is only as good as the reagents that power it.

Celsis<sup>®</sup> utilizes the most advanced class of adenosine triphosphate (ATP) bioluminescence reagents, unlocking new efficiencies for your QC workflow and a new level of confidence in the safety of your product.

**Don't settle for less. Charles River manufactures Celsis AMPiScreen<sup>®</sup> Pharma reagents to the same high-level quality you build into your own products.**



**celsius<sup>®</sup>**

**Method Overview & Applications**

# CELSIS APPLICATIONS

Celsis® Method Overview

**microbial limits**  
**STERILITY**  
**contamination response**

**USP <61>, <62>; EP 2.6.12**

- Products testing negative: pass
- Products testing positive: SOP for enumeration/identification

**USP <71>, EP 2.6.1**

- Trusted for final product sterility in Pharma market

**Non-destructive Test**

- Celsis® Enrichment reserved for rapid retest or investigation



# PRIMARY CONSIDERATIONS

When Choosing an RMM



# ADAPTS TO CURRENT TEST PROTOCOLS

Minimizes Changes to Current Preparation Method


## Sample Type

Capable of testing various sample matrices, sizes, and volumes.



## Culture Media

Compatible with a wide variety of common media: such as TSB, TAT, and FTM



## Test Method

Compatible with Microbial Limits/Bioburden testing and sterility testing via direct inoculation or membrane filtration



## Incubation Time

Microbial Limits and Bioburden in 24 Hours versus 5-7 days. Sterility results in 6 days versus 14 days

# FLEXIBLE PROTOCOL FOR BROAD PRODUCT SUITABILITY

## Celsis AMPiScreen® Method Overview

### Flexible Protocol


- W/ or w/o filtration
- Varying broth volumes/types
- Soluble / Non-soluble products
  - High pH / Low pH products
  - Oil / Water based products
    - Pigmented products
    - Preserved products

### Product Matrix Examples

- IV Solutions, Antibiotics, Vaccines
- Tablets, Syrups, Suspensions
- Lotions, Creams, Ointments, Gels
- Medical Devices, Packaging
- Soaps, Detergents, Fabric Softeners
- Toothpaste, Deodorant, Cosmetics
- Ink, Pudding, Juices, Nutritionals

# EXAMPLE PROTOCOL – MICRO LIMITS TESTING

## Celsis AMPiScreen® Method Overview



### Direct Inoculation

- Measure and prepare sample in broth media (typically TAT, TSB, or Letheen).

### Membrane Filtration

- Filter sample according to preparation method and transfer membrane to broth media for incubation.

### Incubate

- Incubate samples for 24 hours
- For mold detection, add beads and place on linear shaker for 30 minutes after incubation.


### Analyze

- Pipette 50µL of incubated sample into cuvettes and load into instrument.
- After ~1 hr automated analysis, collect results.

A close-up photograph of a laboratory setting. A hand wearing a yellow nitrile glove is holding a clear glass test tube. Below the hand, a multi-well plate is visible, filled with numerous small, clear plastic wells. The background is slightly blurred, showing more laboratory equipment. The overall scene is brightly lit, typical of a clinical or research environment.

**celsius**<sup>®</sup>

For Rapid Sterility Testing



---


**celsius<sup>®</sup>**

**Key Advantages of a Rapid Test Method**

---

# TRADITIONAL METHOD VS CELSIS RMM

Key Advantages of a Rapid Test Method



# DATA INTEGRITY

A Key Advantage to Rapid Sterility Testing Resulting in Improved Data Integrity position



## Subjective evaluation in Traditional Method

- Based on visual, human analysis
- Four-eyes principle requires additional personnel
- Prone to interpretation and transcription error.
- Single canisters compared against control canister for each media type.



# IMPROVED TEST PERFORMANCE

A Key Advantage to Rapid Testing Resulting in Improved Data Integrity position



An example where turbidity is a poor indicator of microbial contamination.

Which are sterile and which are contaminated?

Samples 1 and 2 are **sterile**.

Samples 3 and 4 are **contaminated**.

# DATA INTEGRITY


## Objective Evaluation in Celsis Rapid Detection

- Based on instrument analysis.
- Automation allows walk-away results.
- Automatic results reporting and export removes possibility of interpretation or transcription errors.
- Duplicate cuvettes prepared for each sample compared against duplicate control cuvettes.



# RESULTS INTEGRITY

Subjectivity vs Objectivity: Celsis.im software




## ✓ ASSAY AUTOMATION

- Precisely controls reagent volumes and reaction timing

## ✓ OBJECTIVE RESULTS:

- Interprets results against validated parameters
- Provides multiple reporting options



## ✓ 21 CFR Part 11 compatibility

## ✓ Compatibility up to Windows 10 Pro

## ✓ Archived data protects data integrity

## ✓ Administrator right and users roles/permission structure



celsis®

The support you need from start to finish, and beyond.

# YOUR SUCCESS IS OUR SUCCESS

Industry Leading Expertise And Support



## APPLICATION DEVELOPMENT

- Charles River Application & Development Labs
- Feasibility and Sample Evaluation Testing

## VALIDATION

- IQ / OQ completed with installation
- PQ documentation and validation guides
- Equivalency Report Available
- Coming soon: Method Suitability Services and Protocols

## REGULATORY

- Drug Master Files and Technical Reports
- Strong track record of regulatory acceptance and compliance experience

## TECHNICAL SUPPORT

- Three days of on-site training
- Experienced Technical Account team
- Global network

The background features a stylized industrial scene with various components. On the left, there are large, light blue cylindrical tanks or pipes. In the center, three blue, ring-shaped mechanical parts are arranged in a row. On the right, two brown cardboard boxes are shown on a grey pallet. The entire scene is overlaid with a semi-transparent dark grey horizontal band containing the text.

# OPERATIONAL IMPACT OF CELSIS<sup>®</sup>

Reduced cost of manufacturing

Reduced inventories

Financial Savings

Earlier response to contamination events

Experienced global support through Charles River



# LEADING COMPANIES TRUSTING CELSIS<sup>®</sup> DETECTION

Proven and In Use by Pharma and Personal Care  
Product Manufacturers



AVON



ESTÉE LAUDER

P&G


STERIS<sup>®</sup>



charles river

# CRITICAL INFORMATION TO RELEASE PRODUCT FASTER

Increased Efficiencies of a Qualitative Screening Assay



→ **Products test negative:  
rapid release**

REDUCED INVENTORY AND COST  
TO MANUFACTURE


→ **Products test positive:  
rapid response**

REDUCED CONTAMINATION COSTS




# REDUCING INVENTORY AND LEAD TIMES

The Cost Savings from Charles River RMMs




# REDUCING INVENTORY AND LEAD TIMES

The Cost Savings from Charles River RMMs



# HIDDEN COSTS ADD TO TRUE COST PER TEST


The Cost Savings from Charles River RMMs




# FINANCIAL IMPACT ASSESSMENT


## The Cost Savings from Charles River RMMs

Using **readily available** financial and QC data, the following can be determined:

 Net Present Value over 5 years

 Payback Period Calculation

 Annual Containment Savings

 Calculates single and multi-site implementations

Business Specific Input	
Begin first period	Jun-15
Cost of Capital	10.0%
Stock carrying cost	20.0%
Value of Daily Finished Goods Output (\$,£,€)	100,000
Space needed for daily output (Sq.Unit.)	1,500
Warehouse space cost (\$,£,€)/Sq Unit/Annum)	10.00
Lab technician salary & benefits (\$,£,€)	60,000
Testing	
Validation tests per product	25
Number of products for validation	20
Number of tests per year	5,000
Quarantine days -Current	5
Quarantine days -Celsius	1
Current test cost	4.00
Celsius test cost	7.75
Fixed Transfer Costs	
Equipment purchase	97,657
Validation Support	

Calculated Results	
Five-year Net Present Value (\$,£,€)	1,215,591
Payback Period (Months)	7.88
Annualized Containment Savings (\$,£,€)	100,000

Risk Management of Contamination Events	
Frequency (Occur./Yr)	0.50
Loss Factor	50%
Current days to detection	5
Proposed days to detection	1

Include Safety Stock Savings?	
Enter Yes or No	yes

Implementation by Period	
Period 1	50.0%
Period 2	100.0%
Period 3	100.0%
Period 4+	100.0%

# SUMMARY AND NEXT STEPS

01

## **Celsis Rapid Microbial Detection...**

builds on experience of traditional methods, but offsets the limitations.

02

## **Celsis AMPiScreen Method...**

offers simplicity, flexibility, and rapid results.

03

## **Charles River Microbial Solutions Support...**

provides a global partner to achieve successful implementation.

### NEXT STEPS

- Establish multi-function team and project timeline
- Complete and review Financial Impact Assessment
- Review products for validation and implementation



# CONTACT US

ENTER CONTACT INFO HERE

**Address:**

**251 Ballardvale Street  
Wilmington, MA  
01887**

**Email:**

**[askcharlesriver@crl.com](mailto:askcharlesriver@crl.com)**

**Website:**

**[www.criver.com](http://www.criver.com)**

**Phone:**

**877.CRIVER.1**



---

# APPENDIX

---

Additional Information

# RMM TECHNOLOGY SELECTION



**Growth Based Methods Detectable signal is achieved after a period of growth**

- Amplified ATP Bioluminescence
- CO2 Production
- Flow Cytometry
- Fluorescence-Assisted Colony Counter
- Standard ATP Bioluminescence
- Digital Imaging Technology

**Direct Measurement: Individual cells are differentiated and visualized**

- Flow Cytometry
- Solid Phase cytometry



# REGULATORY OVERVIEW

Industry Leading Expertise And Support

Regulators do not pre-approve RMM technologies; the user is responsible for seeking approval of use with their products, process, and method.



## Already in Use

- A growing number of companies have received approval for the use of Celsis for finished product testing using various submission strategies



## Guidance for the Validation of Rapid Microbial Methods

- PDA TR33
- USP<1223>
- Ph. Eur. 5.1.6

# PRIMARY CONSIDERATIONS IN SELECTING AN RMM TECHNOLOGY

TECHNOLOGY	PRODUCT APPLICATION	TIME TO RESULT	THROUGHPUT	VIABILITY	ADOPTION
Amplified ATP Bioluminescence	Broad (Celsis)	18-24 h	High	Non-destructive	800 Global Instruments
CO <sub>2</sub> Production	Broad	48-72 h	Low	Non-destructive	Limited Clinical
Solid & Flow Cytometry	Limited	9-50 h	Low	Destructive	Limited
Fluorescence	Limited	24-48+ h	Low	Non-destructive	Limited
ATP Bioluminescence	Limited (filter)	24-48+ h	Low	Non-destructive	Limited

# TIERS OF REGULATORY REQUIREMENTS

## Appendix A

	US / FDA / USP		EU / EMA / EP	
	Validation Required	Submission required	Validation Required	Submission required
OTC Over the Counter	✓	No	✓	No
In-process Testing	✓	Not typically unless micro commitments made in filing	✓	Typically ✓
Non-sterile Regulated	✓	✓	✓	✓
Sterile Regulated	✓	✓	✓	✓

# PDA TR33 GUIDANCE

## Appendix B

PDA TR33 Validation Criteria	Qualitative Method	User or Supplier Demonstrated	Celsis Approach	
Equivalence / Comparative Testing	Yes	User	Equivalency Protocol	✓
Limit of Detection	Yes	User	Generated from Equivalency Protocol	✓
Method Suitability	Yes	User	Typical Celsis Sample Effects	✓
Specificity	Yes	User	Typical Celsis Spiking studies	✓
Ruggedness	Yes	Supplier	Technical Report TR120407-04	✓
Robustness	Yes	Supplier	Technical Report TR120408-02	✓
			Drug Master File	✓

# PROACTIVE QUALITY SYSTEMS REDUCE RISK

What if you do find a positive result?

The cosmetic products industry has a known history of recall notices that name the following organisms as microbial contaminants: *B. cepacia*, *P. aeruginosa*, *S. aureus*, *E. coli.*, *K. pneumoniae*, and *S. marcescens*.

Aside from the obvious concern for consumer safety, a microbial contamination is also costly in terms of immediate financial impact and longer-term damage to the brand's reputation.

So how can you reduce the risk of a product recall associated with these and other known harmful organisms?

- Environmental monitoring
- Accurate and reliable microbial identification
- Tracking and trending EM data




# THE IMPORTANCE OF ACCURATE IDENTIFICATIONS & EM

- The first step in most risk-reduction approaches is identification and characterization of the objectionable organism.
- The next step is accurate identification, which can only occur if the organism is present in the microbial library that is referenced.
- Environmental monitoring (EM) is a fundamental aspect of cGMP compliance and is a proven strategy for contamination risk mitigation for cosmetic manufacturers.
- Accurate identification of environmental isolates plays an important role in this strategy because it helps record the routine flora of the facility and allows the quality system managers to detect and analyze any deviations from the norm.

## The Environmental Monitoring Program

- Measures and documents the **State of Control** of the facility
- Quality of the environment
- Acts as early warning surveillance system



## The Isolate of Concern

- **Risk management** - Evaluate level of risk
- Origin of contamination
- Is the isolate objectionable?
- CAPA planning to mitigate risk

# WHY TREND ORGANISMS?

Turning Raw Data into Actionable Information




When you have confidence in your ID results, you can gain a better understanding of your manufacturing environment and the ability to aggregate and trend EM data.



But collecting and managing this data can be difficult and time-consuming, which is why having the right tool to automate these processes can lead to significant time (and cost) savings.

# SUPERIOR DATA LEADS TO SUPERIOR CONTROL



**IMPROVED TEST METHODS**



**RECORDS MANAGEMENT**



**DATA INTEGRITY**